# Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

> **NCT03620435** · PHASE2 · UNKNOWN · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 25 (estimated)

## Conditions studied

- Safety Issues

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03620435
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2020-05-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620435, "Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03620435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*